Under the terms of the agreement, Nuvisan will initiate a stage-gated work program to evaluate multiple distinct MC payload variants developed by Simris Biologics. The study will start with lab-based tests (in vitro efficacy) to see how well these compounds work against cancer cells. The most promising candidates will then move on to testing in living models (in vivo tolerability) to assess safety and potential side effects. Additionally, we’ll test how these drug candidates interact with immune cells from human blood to better understand their potential impact.

In a follow-up study, the top-performing candidate will be tested further to evaluate how well the ADC works against cancer in a living system (in vivo efficacy).

The project will leverage a commercially available monoclonal antibody, eliminating the need for de novo antibody generation and enabling rapid advancement.

Key features of the collaboration include:

• Use of a cost-efficient, clinically relevant antibody
• Initial in-vitro efficacy test expected to take about 1.5 months
• In-vivo tolerability studies expected to be completed within 3 months
• Additional testing with human immune cells to support selection of the best drug candidate

“This agreement marks an important milestone for Simris Biologics as we advance our next-generation ADC payloads into in-vivo testing,” said Dr Alexis Roberts-McIntosh, CEO, Simris Group AB. “Nuvisan’s deep expertise in translational research and clinical development makes them an ideal partner as we accelerate our path toward clinical validation.”

The collaboration reflects Simris’ commitment to developing novel, cyanobacteria-derived toxin payloads with improved therapeutic windows and differentiated mechanisms of action.

For more information about Simris Biologics, please visit: https://simrisbiologics.com
For more information about Nuvisan, visit: https://www.nuvisan.com